Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

AN OPEN-LABEL, MULTI-CENTER, LONG-TERM EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ADMILPARANT IN PARTICIPANTS WITH PULMONARY FIBROSIS

Intervention/treatment:
ADMILPARANT (BMS-986278)
Medical condition:
PULMONARY FIBROSIS
Protocol code:
IM027-1016
Control number:
307293
Status:
Not yet recruiting
Approved:
April 07, 2026
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07441408
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role
CONTACT
Phone:
855-907-3286
Name
First line of the email MUST contain NCT # and Site #.
Role
CONTACT
Sponsor
BRISTOL-MYERS SQUIBB CANADA

Locations

Alberta

Local Institution - 0166
Sherwood Park, Alberta, T8H 0N2
Name
Site 0166
Role
CONTACT

British Columbia

Local Institution - 0165
Vancouver, British Columbia, V5Z 1M9
Name
Site 0165
Role
CONTACT
Local Institution - 0168
Vancouver, British Columbia, V6Z 1Y6
Name
Site 0168
Role
CONTACT

Ontario

Local Institution - 0163
Owen Sound, Ontario, N4K 6M9
Name
Site 0163
Role
CONTACT
Local Institution - 0167
Burlington, Ontario, L7N 3V2
Name
Site 0167
Role
CONTACT
Local Institution - 0169
Toronto, Ontario, M5T 3A9
Name
Site 0169
Role
CONTACT
Local Institution - 0170
Hamilton, Ontario, L8N 4A6
Name
Site 0170
Role
CONTACT

Quebec

Local Institution - 0164
Trois-Rivières, Quebec, G8T 7A1
Name
Site 0164
Role
CONTACT
Local Institution - 0171
Greenfield Park, Quebec, J4V 2H1
Name
Site 0171
Role
CONTACT
Local Institution - 0172
Montreal, Quebec, H2X 1R9
Name
Site 0172
Role
CONTACT
Local Institution - 0173
Trois-Rivières, Quebec, G9S4P3
Did you find what you were looking for?